Clinical Trial

Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

Study acronym: TRANSPGx
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-20; most recent amendment 2025-09-04.
Status change: Not Yet Recruiting → Recruiting 2025-09-04
Trial Details
NCT Number NCT06701825
Lead Sponsor Instituto de Investigación Hospital Universitario La Paz
Collaborators: Instituto de Salud Carlos III
Conditions Kidney Disease, Chronic, Transplant Recipient (Kidney), Immunosuppression
Enrollment 114 participants
Start Date 2025-06-02
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-11